ClinicalTrials.gg

Program

repinatrabit

Also written as “JNT-517 Tablet”, “JNT-517” and “Repinatrabit”.

Its studies are mostly in Phenylketonurias, led by Otsuka.

Furthest: phase 3, since Oct 2, 20247 company-led studies, 4 open or runningNext primary completion: Feb 9, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka74 open or runningphase 3since Oct 2, 2024Feb 11, 2023Feb 9, 2027phase 1 · NCT07713758

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2023First study: phase 2 study in PhenylketonuriasFirst studyNCT05781399 · 163 enrolled · United States, Australia
  2. Oct 2, 2024Phase 3 study in PhenylketonuriasNCT06628128 · 240 planned · United States, Australia
  3. Oct 7, 2024Phase 2 study in PhenylketonuriasNCT06637514 · 14 enrolled · United States, Australia
  4. May 7, 2025Phase 3 study in PhenylketonuriasNCT06971731 · 120 planned · United States, Australia, Canada and more
  5. Feb 25, 2026Phase 1 study in PhenylketonuriasNCT07446400 · 48 planned · Australia
  6. Apr 30, 2026Phase 1 study in Healthy VolunteersNCT07573449 · 8 enrolled · United States
  7. Jul 15, 2026Phase 1 study in PhenylketonuriasNCT07713758 · 32 planned · United States

Ahead

  1. Nov 7, 2026Primary completion: phase 1 study in PhenylketonuriasNCT07446400
  2. Feb 9, 2027Primary completion: phase 1 study in PhenylketonuriasNCT07713758
  3. Nov 1, 2027Primary completion: phase 3 study in PhenylketonuriasNCT06628128
  4. Mar 1, 2028Primary completion: phase 3 study in PhenylketonuriasNCT06971731

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07713758Phenylketonurias · United States1RecruitingFeb 9, 202732
NCT07573449Healthy Volunteers · United States1CompletedJan 22, 20258
NCT07446400Phenylketonurias · Australia1RecruitingNov 7, 202648
NCT06971731Phenylketonurias · United States, Australia, Canada and more3RecruitingMar 1, 2028120
NCT06637514Phenylketonurias · United States, Australia2CompletedMay 8, 202614
NCT06628128Phenylketonurias · United States, Australia3RecruitingNov 1, 2027240
NCT05781399Phenylketonurias · United States, Australia2CompletedJul 29, 2025163

How it is read

Names in the registry

  • “JNT-517 Tablet”, 3 entries
  • “JNT-517”, 2 entries
  • “Repinatrabit”, 2 entries
  • “JNT-517 Suspension”, 1 entry
  • “[14C]-JNT-517”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.